Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
10.18
+0.68 (7.16%)
At close: May 12, 2025, 4:00 PM
10.18
0.00 (0.00%)
After-hours: May 12, 2025, 4:39 PM EDT
Nurix Therapeutics Stock Forecast
Stock Price Forecast
The 17 analysts with 12-month price forecasts for Nurix Therapeutics stock have an average target of 30.71, with a low estimate of 16 and a high estimate of 41. The average target predicts an increase of 201.67% from the current stock price of 10.18.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Nurix Therapeutics stock from 17 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 7 | 7 | 7 | 7 | 7 |
| Buy | 8 | 9 | 9 | 9 | 8 | 8 |
| Hold | 1 | 1 | 1 | 1 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 17 | 17 | 17 | 17 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $27 | Strong Buy | Reiterates | $27 | +165.23% | Apr 29, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $32 → $25 | Buy | Maintains | $32 → $25 | +145.58% | Apr 9, 2025 |
| Stifel | Stifel | Strong Buy Maintains $36 → $35 | Strong Buy | Maintains | $36 → $35 | +243.81% | Apr 9, 2025 |
| Needham | Needham | Strong Buy Maintains $28 → $27 | Strong Buy | Maintains | $28 → $27 | +165.23% | Apr 9, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $36 | Strong Buy | Reiterates | $36 | +253.63% | Apr 2, 2025 |
Financial Forecast
Revenue This Year
63.13M
from 54.55M
Increased by 15.73%
Revenue Next Year
59.96M
from 63.13M
Decreased by -5.01%
EPS This Year
-3.09
from -2.88
EPS Next Year
-3.32
from -3.09
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 93.7M | 99.8M | 214.5M | ||
| Avg | 63.1M | 60.0M | 84.9M | ||
| Low | 18.1M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 71.8% | 58.0% | 257.8% | ||
| Avg | 15.7% | -5.0% | 41.6% | ||
| Low | -66.8% | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.14 | -1.70 | -1.63 | ||
| Avg | -3.09 | -3.32 | -3.15 | ||
| Low | -3.49 | -4.51 | -4.07 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.